year
mark
anniversari
approv
unit
state
food
drug
administr
us
fda
rituximab
daclizumab
treatment
b
cell
malign
use
suppress
organ
reject
renal
transplant
respect
tabl
two
antibodi
previous
approv
fda
tabl
approv
watersh
moment
histori
monoclon
antibodi
mab
therapeut
reason
differ
molecul
becom
huge
medic
commerci
success
indic
b
cell
malign
well
treatment
rheumatoid
arthriti
ra
storz
current
fourth
bestsel
innov
drug
kind
worldwid
sale
mm
tabl
sale
come
cancer
indic
sale
treatment
ra
la
meri
publish
includ
seven
top
ten
sell
innov
drug
world
protein
six
antibodi
relat
molecul
tabl
hand
first
human
antibodi
fda
approv
never
achiev
signific
commerci
success
eventu
withdrawn
market
daclizumab
howev
approv
recent
tradenam
treatment
relaps
form
multipl
sclerosi
ms
date
uniqu
innov
antibodi
fc
fusion
protein
approv
treatment
diseas
least
one
major
market
ie
us
eu
japan
tabl
seven
withdrawn
market
either
due
lack
efficaci
poor
toxic
efficaci
profil
lack
market
interest
tabl
approv
antibodybas
molecul
five
contain
complet
murin
sequenc
nine
mousehuman
chimer
antibodi
human
human
antibodi
fc
fusion
tabl
fulli
human
antibodi
deriv
transgen
human
mice
six
deriv
human
antibodi
phage
display
librari
tabl
eight
fc
fusion
fcprotein
fusion
two
fcpeptid
fusion
one
fcprotein
fusion
tissuetarget
peptid
fuse
current
phase
iii
clinic
stage
candid
well
known
phase
phase
ii
antibodybas
clinic
candid
tabl
thu
may
least
known
antibodi
fc
fusion
protein
clinicalstag
candid
tabl
nake
igg
nake
antibodi
fragment
case
nake
refer
antibodi
antibodydrug
conjug
adc
bispecif
antibodi
radioimmunotherapeut
immunocytokin
adc
bispecif
antibodi
fc
fusion
protein
conjug
radioisotop
either
therapeut
imag
agent
immunocytokin
tabl
fig
notabl
except
fc
fusion
protein
non
nake
antibodi
skew
toward
phase
iii
clinic
stage
like
due
recent
develop
variou
innov
technolog
incorpor
molecul
tabl
addit
protein
antibodyderiv
clinic
stage
molecul
document
phase
ii
clinic
stage
chimer
antigen
receptor
car
cell
natur
killer
nk
cell
candid
incorpor
antibodi
car
tabl
fig
thu
least
protein
cell
base
antibodyderiv
construct
either
approv
medic
use
evalu
safeti
efficaci
clinic
trial
uniqu
antibodybas
moleculescel
develop
approv
therapeut
use
tabl
target
uniqu
antigen
tabl
sever
target
import
multipl
diseas
area
eg
vascular
endotheli
growth
factor
vegf
signific
target
oncolog
ophthalmolog
indic
use
list
antibodi
thu
uniqu
molecul
use
differ
major
therapeut
area
indic
tabl
uniqu
target
distribut
amongst
major
use
tabl
protein
recombin
cellbas
candid
direct
target
oncolog
tabl
surprisingli
current
cart
carnk
candid
clinic
evalu
cancer
indic
howev
preclin
effort
gener
cart
cell
virus
virusinfect
cell
target
sahu
et
al
liu
et
al
hale
et
al
may
chang
near
futur
anoth
clinic
candid
direct
target
immunolog
therapeut
area
includ
autoimmun
asthma
exclud
ms
tabl
remain
ca
antibodybas
protein
divid
amongst
therapeut
area
includ
cardiovascular
metabol
neurobiolog
bone
muscl
disord
blood
disord
infecti
diseas
differ
use
target
singlepass
membran
bound
protein
cellbound
protein
eg
receptor
tyrosin
kinas
aka
egfr
epitheli
growth
factor
receptor
receptor
tyrosin
kinas
aka
anoth
gcoupl
protein
receptor
gpcr
eg
cc
motif
chemokin
receptor
cc
motif
chemokin
receptor
cxc
motif
chemokin
receptor
multipass
eg
steap
sixtransmembran
epitheli
antigen
prostat
famili
member
cell
surfac
target
addit
solubl
target
eg
tnf
tumor
necrosi
factoralpha
vegfa
vascular
endotheli
growth
factor
infecti
diseas
target
eg
respiratori
syncyti
viru
rsv
f
protein
bacillu
anthraci
protect
antigen
pa
toxin
compon
influenza
hemagglutinin
stalk
portion
human
immunodefici
viru
hiv
envelop
protein
tabl
cell
surfac
target
oncolog
tend
fall
three
categori
first
categori
includ
receptor
eg
epcam
epitheli
cell
adhes
molecul
epcam
carcinoembryon
antigen
relat
cell
adhes
molecul
mucin
cell
surfac
associ
essenti
postal
address
kill
mechan
target
directli
kill
mechan
includ
either
individu
combin
antibodydepend
cellular
cytotox
adcc
ochoa
et
al
antibodydepend
cellular
phagocytosi
adcp
shi
et
al
complementdepend
cytotox
cdc
taylor
lindorf
antibodydrug
conjug
adc
tsuchikama
beck
et
al
antibodyinduc
apoptosi
sun
et
al
wang
et
al
antibodyinduc
nonapoptot
program
cell
death
alduaij
et
al
bispecif
antibodyredirect
killer
nk
cell
lum
thakur
satta
et
al
suzuki
et
al
cartcarnk
cell
ruella
gill
ruella
june
smith
et
al
second
group
overlap
first
group
receptor
may
target
block
ligand
bind
signal
transduct
esparisogando
et
al
zhang
zhang
final
categori
checkpoint
modul
either
block
cell
inhibitori
pathway
directli
stimul
nk
cell
macrophag
tcell
relat
oncolog
target
categori
uniqu
target
antibodybas
drug
candid
wide
target
antigen
recogn
clinic
candid
car
tabl
second
target
protein
found
clinic
stage
approv
molecul
cellredirect
bispecif
antibodi
candid
tabl
thu
two
top
target
respons
engin
retarget
cell
either
cart
cell
ruella
gill
ruella
june
smith
et
al
tcell
redirect
bispecif
antibodi
lum
thakur
satta
et
al
suzuki
et
al
kill
cancer
cell
nontcel
relat
target
protein
current
wide
target
egfr
msln
mesothelin
cancer
indic
cytokin
antibodyrel
biolog
direct
current
top
nononcolog
target
tabl
uniqu
molecul
recombin
car
direct
top
target
shown
tabl
repres
clinic
stage
approv
antibodybas
moleculescel
remain
candid
target
remain
uniqu
target
approv
mab
fc
fusion
protein
direct
uniqu
target
tnf
wide
target
five
antibodybas
molecul
tabl
five
valuabl
target
approv
mab
fc
fusion
protein
tnf
vegf
tabl
antibodi
first
four
target
approv
ten
year
ago
market
valu
built
time
remark
howev
antibodi
approv
make
fast
rise
target
valu
tabl
top
ten
antibodybas
therapeut
target
tabl
compris
valu
total
target
antitnf
molecul
lead
way
market
share
tabl
base
sale
figur
recombin
protein
compris
seven
top
best
sell
drug
worldwid
tabl
seven
protein
five
mab
one
fc
fusion
protein
tabl
final
sinc
januari
past
year
antibodi
fc
fusion
protein
compris
innov
unit
state
food
drug
administr
us
fda
drug
approv
fig
repres
greatest
percentag
ever
sinc
begin
antibodi
era
thu
clear
mab
fc
fusion
protein
make
enorm
impact
pharmaceut
industri
novel
approach
treat
difficult
diseas
meet
unmet
medic
need
well
provid
excit
new
growth
area
industri
human
igg
engin
multitud
way
gener
differ
effect
strohl
strohl
shown
tabl
earlier
day
antibodi
engin
focu
manipul
variabl
region
human
affinitymatur
antibodi
gener
differ
type
antibodi
fragment
scfv
bird
et
al
huston
et
al
diabodi
hollig
et
al
pegyl
fab
choy
et
al
tandab
kipriyanov
et
al
domain
antibodi
ward
et
al
next
wave
antibodi
engin
focus
gener
applic
fit
purpos
antibodi
strohl
tune
fc
function
increas
adcc
adcp
cdc
strohl
strohl
brezski
georgiou
sondermann
szymkowski
barnhart
quigley
mute
silenc
fc
function
labrijn
et
al
vafa
et
al
schlothauer
et
al
lo
et
al
borrok
et
al
function
approach
use
glycoengin
strategi
low
fucosyl
higher
bind
increas
adcc
shield
et
al
ferrara
et
al
malphett
et
al
golay
et
al
higher
level
sialyl
dampen
immun
respons
anthoni
ravetch
nonglycosyl
antibodi
partli
subdu
fc
effector
function
walker
et
al
nesspor
et
al
fc
effector
modul
also
gener
amino
acid
chang
lower
hing
fc
shield
et
al
lazar
et
al
strohl
strohl
strohl
vafa
et
al
brezski
georgiou
sondermann
szymkowski
barnhart
quigley
current
three
approv
antibodybas
molecul
modifi
fc
function
includ
fusion
protein
abatacept
belatacept
modifi
hing
reduc
fc
function
davi
et
al
human
mab
eculizumab
hybrid
fc
reduc
fc
function
rother
et
al
three
molecul
bind
immun
system
compon
mute
fc
design
intend
increas
safeti
margin
addit
two
glycoengin
antibodi
improv
adcc
activ
approv
least
one
major
market
first
mogamulizumab
afucosyl
mab
approv
japan
adult
tcell
leukemialymphoma
produc
cell
line
mutat
gene
technolog
biowa
yamaneohnuki
et
al
kanda
et
al
malphett
et
al
second
obinutuzumab
mab
low
fucos
content
approv
treatment
chronic
lymphocyt
leukemia
cll
golay
et
al
low
fucos
obinutuzumab
due
addit
produc
cell
line
iii
gntiii
gene
add
bisect
n
acetylglucosamin
glcnac
interfer
fucosyl
glycart
technolog
acquir
roch
ferrara
et
al
moreov
four
glycoengin
low
fucos
one
aglycosyligg
phase
iii
clinic
candid
late
stage
clinic
pipelin
current
approv
igg
amino
acidmodifi
increas
fc
effector
function
although
two
fcmodifi
increas
fc
effector
function
igg
late
stage
clinic
trial
mab
morphosi
xencor
phase
iiiii
clinic
trial
treatment
b
cell
malign
mab
margetuximab
merck
macrogen
phase
iii
clinic
trial
breast
cancer
moreov
mani
effort
modul
aspect
igg
biolog
beyond
increas
decreas
fc
effector
function
tabl
first
modul
halflif
via
modifi
interact
fc
recycl
receptor
fcrn
roopenian
akilesh
baker
et
al
import
modif
yte
mutat
dall
aqua
et
al
dall
aqua
et
al
medimmun
astrazeneca
incorpor
earli
stage
candid
point
robbi
et
al
halflif
extens
mutat
fc
also
made
includ
xencor
xtend
technolog
zalevski
et
al
incorpor
least
two
earli
stage
clinic
candid
alexion
mab
nation
institut
health
nih
mab
sever
igg
engin
technolog
report
potenti
modul
capabl
exist
futur
clinic
candid
tabl
includ
proteas
activ
probodi
igg
tumorloc
activ
erster
et
al
desnoy
et
al
polu
lowman
proteaseresist
igg
stabl
tumor
microenviron
kinder
et
al
hexamer
antibodi
high
bind
concomit
cdc
effector
function
cook
et
al
de
jong
et
al
phdepend
bind
igawa
et
al
chaparrorog
et
al
devanaboyina
et
al
sweep
antibodi
igawa
et
al
improv
upon
elimin
profil
solubl
antigen
igawa
et
al
engin
variabl
region
improv
solubl
develop
clark
et
al
seelig
et
al
modul
pi
charg
antibodi
variabl
sequenc
improv
halflif
igawa
et
al
li
et
al
dattamannan
et
al
andor
separ
purif
sampei
et
al
mutat
protein
bind
site
improv
purif
heterobispecif
igg
tustian
et
al
anoth
area
antibodi
engin
start
see
signific
activ
engin
igm
therapeut
especi
high
avid
effect
desir
chromikova
et
al
wang
et
al
recent
exampl
igm
demonstr
greater
avid
greater
kill
effect
similar
igg
wang
et
al
adc
target
cytotox
drug
tumor
kill
cancer
cell
lower
system
exposur
activ
moieti
goal
increas
size
efficacytox
window
highli
toxic
antitumor
drug
strohl
strohl
tsuchikama
beck
et
al
adc
consist
three
compon
target
antibodi
cytotox
payload
linker
coupl
two
compon
togeth
fig
three
compon
come
five
consider
design
construct
adc
first
target
antibodi
must
bind
protein
found
either
exclus
cancer
cell
significantli
overexpress
cancer
cell
compar
express
normal
tissu
best
target
adc
may
oncofet
antigen
target
may
overexpress
cancer
cell
present
normal
tissu
low
copi
number
tissu
toxic
toler
cell
surfac
protein
wide
target
clinic
stage
approv
adc
current
five
adc
target
four
adc
target
three
adc
target
mesothelin
adc
target
egfr
wildtyp
egfr
variant
iii
two
clinic
stage
adc
target
properti
good
adc
target
well
descript
candid
adc
target
review
teicher
strohl
strohl
interest
strategi
employ
cytomx
increas
tumor
specif
adc
use
proantibodi
possess
peptid
sequenc
cover
paratop
prevent
bind
target
reach
tumor
microenviron
tme
tme
paratopeshield
peptid
cleav
matrix
metalloproteinas
mmp
high
concentr
tme
allow
antibodi
bind
target
local
environ
desnoy
et
al
polu
lowman
second
adcdirect
antibodi
must
rapidli
intern
upon
ligat
target
receptor
antibodi
bind
cell
surfac
receptor
may
may
intern
rapidli
isol
antibodi
incorpor
intern
screen
discoveri
process
critic
poul
et
al
zhou
et
al
third
ident
number
type
linker
attach
site
critic
issu
first
gener
adc
linker
typic
attach
lysin
residu
tsuchikama
beck
et
al
given
lysin
residu
typic
igg
ten
access
chemic
coupl
tsuchikama
result
conjug
highli
heterogen
even
optim
conjug
lysin
result
drug
antibodi
ratio
dar
rang
lazar
et
al
tsuchikama
beck
et
al
multipl
challeng
heterogen
adc
includ
analyt
challeng
batchtobatch
consist
stabil
adc
potenti
variabl
pharmacokinet
conjug
site
antibodi
interfer
normal
fcrnmediat
recycl
beck
et
al
site
specif
conjug
achiev
varieti
method
result
tight
dar
increas
homogen
junutula
et
al
panowski
et
al
perez
et
al
beerli
et
al
ihospic
et
al
siegmund
et
al
thompson
et
al
tsuchikama
beck
et
al
appear
signific
advanc
new
approach
use
extens
sequenc
develop
mersana
achiev
drugantibodi
ratio
yurkovetskiy
et
al
fourth
stabil
linker
huge
influenc
efficaci
toxic
adc
theori
stabl
linker
degrad
within
lysosom
best
safeti
profil
unfortun
simpl
case
highli
stabl
linker
result
safeti
issu
may
due
mannos
receptor
potenti
also
bind
intern
adc
could
result
offtarget
toxic
issu
gorovit
krinoskiorotti
beck
et
al
final
cancer
cell
within
tumor
target
antigenposit
singh
et
al
thu
allow
potenti
escap
antigenneg
cell
target
therapi
demonstr
membran
permeabl
cytotoxin
critic
factor
potenti
bystand
activ
li
et
al
thu
design
futur
adc
need
take
chemistri
result
adc
account
optim
bystand
effect
efficaci
current
clinic
stage
adc
includ
three
approv
adc
nine
phase
iii
develop
anoth
phase
iii
clinic
develop
three
approv
adc
includ
withdrawn
target
clinic
stage
adc
molecul
direct
least
differ
known
target
although
disclos
actual
number
may
higher
target
cell
surfac
receptor
current
adc
msln
mesothelin
adc
known
differ
class
drug
incorpor
clinic
stage
adc
small
molecul
class
five
proteinbas
wide
use
drug
class
incorpor
clinic
stage
adc
auristatin
employ
time
follow
maytansanoid
adc
benzodiazepin
use
adc
tabl
biolog
pseudomona
exotoxin
incorpor
four
adc
tabl
even
though
three
adc
approv
therapeut
use
technolog
still
rel
earli
development
cycl
mani
rule
optim
adc
still
sort
drake
rabuka
beck
et
al
detail
design
construct
adc
found
tsuchikama
beck
et
al
fc
fusion
fusion
igg
fc
domain
either
protein
peptid
theori
fusion
either
c
nterminu
fc
fc
fusion
market
clinic
develop
today
ntermin
fusion
primari
reason
gener
fc
fusion
extend
halflif
pharmacolog
relev
protein
peptid
use
fcrnmediat
recycl
fc
strohl
strohl
strohl
current
fc
fusion
protein
approv
therapeut
use
tabl
three
phase
iii
clinic
trial
evalu
earlier
stage
clinic
trial
tabl
mani
earlier
fc
fusion
gener
construct
use
receptor
exodomain
immun
pathway
eg
receptor
fuse
fc
modul
immun
system
either
block
solubl
cytokin
bind
cell
recent
fc
fusion
protein
becom
divers
strohl
pharmacolog
activ
head
group
blood
factor
factor
ix
factor
viii
peptid
gcg
thpo
thrombopoietin
analogu
enzym
tissu
nonspecif
alkalin
phosphatas
tnsalp
millan
et
al
asfotas
alfa
hofman
et
al
certain
human
cytokin
approv
market
name
system
deliveri
use
sever
diseas
metastat
melanoma
metastat
renal
cell
carcinoma
dutcher
system
deliveri
cellactiv
cytokin
howev
bring
potenti
advers
event
concept
use
antibodi
target
cytokin
either
tumor
specif
tissu
came
fruition
around
turn
centuri
penichet
morrison
halin
et
al
sinc
time
effort
target
cytokin
tnf
tumor
microenviron
desir
activ
take
place
reduc
advers
system
effect
neri
sondel
approach
actual
fusion
cytokin
antibodi
make
immunocytokin
may
target
vasculatur
associ
tumor
pasch
et
al
hemmerli
neri
tumor
cell
surfac
antigen
klein
et
al
target
would
assist
accumul
inflam
joint
hugh
et
al
immunocytokin
come
two
major
format
cytokinescfv
fragment
fusion
short
circul
halflif
cytokineigg
fusion
retain
long
halflif
neri
sondel
least
immunocytokin
current
evalu
clinic
trial
two
fibronectin
extra
domain
b
edb
target
scfv
fusion
edbtarget
scfv
fusion
phase
iii
pivot
clinic
trial
combin
therapi
malign
melanoma
clinic
stage
immunocytokin
includ
exampl
fibronectin
extra
domain
eda
target
scfv
fusion
phase
ii
treatment
ra
tenascin
c
altern
splice
variant
scfv
fusion
phase
treatment
acut
myeloid
leukemia
aml
fap
fibroblastactiv
protein
fusion
phase
treatment
solid
tumor
cergutuzumab
amunaleukin
anticea
carcinoembryon
antigenigg
fuse
current
phase
clinic
trial
treatment
solid
tumor
antibodydirect
modul
immun
cell
checkpoint
receptor
becom
one
excit
import
new
area
antibodi
therapeut
past
year
effort
focus
cell
checkpoint
modul
increas
interest
b
cell
nk
cell
myeloid
cell
checkpoint
modul
well
cell
activ
regul
seri
three
signal
first
signal
provid
interact
cell
receptor
tcr
major
histocompat
complex
mhc
hla
class
cell
mhc
hla
class
ii
cell
antigen
present
cell
apc
secondari
signal
provid
one
sever
checkpoint
receptor
tabl
either
provid
costimulatori
signal
activ
cell
block
signal
dampen
cell
respons
topalian
et
al
third
signal
come
product
either
proinflammatori
cellactiv
cytokin
antiinflammatori
cytokin
would
act
reduc
cell
respons
chikuma
et
al
schirdewahn
et
al
cancer
cell
express
ligand
cell
inhibitori
receptor
ligand
pd
ligand
aka
ligand
report
inhibit
cell
activ
cytolyt
cell
respons
ligat
receptor
lead
cell
anergi
exhaust
result
inabl
immun
system
kill
cancer
cell
inhibit
block
respons
cell
activ
use
antibodi
proven
clinic
result
improv
respons
subset
patient
metastat
melanoma
nsclc
potenti
form
cancer
achkar
tarhini
kim
et
al
addit
effort
ongo
use
combin
antibodi
increas
percentag
patient
experienc
durabl
respons
ie
rais
tail
surviv
curv
harri
et
al
altern
sever
clinic
candid
agonist
tcell
activ
receptor
gitr
ico
stimul
cell
respons
antonia
et
al
tabl
addit
cell
checkpoint
pathway
potenti
import
infecti
diseas
cell
exhaust
halt
cell
elimin
viral
bacteri
pathogen
dyck
mill
final
antibodi
intervent
cell
checkpoint
pathway
may
play
role
autoimmun
diseas
block
activ
signal
increas
block
signal
may
result
lower
cell
activ
respons
van
der
vlist
et
al
five
mab
two
fc
fusion
protein
target
cellapc
checkpoint
approv
tabl
two
cell
checkpoint
inhibitor
antibodi
current
phase
iii
clinic
trial
phase
iii
clinic
trial
cover
differ
cell
checkpoint
target
checkpoint
target
test
immun
oncolog
relat
diseas
exampl
antagonist
earli
stage
clinic
trial
treatment
variou
immun
disord
wherea
agonist
earli
stage
clinic
trial
variou
cancer
indic
tabl
checkpoint
ligand
express
cancer
cell
also
potenti
excel
target
block
inhibitori
checkpoint
interact
well
target
ligandexpress
cancer
cell
fcactiv
antibodi
approach
three
approv
antibodi
anoth
seven
clinic
trial
well
three
clinic
stage
ligand
mab
one
cart
cell
product
phase
clinic
trial
well
four
antibodi
current
phase
clinic
trial
b
cell
transit
checkpoint
center
around
b
cell
homeostasi
choic
whether
b
cell
matur
proceed
apoptosi
process
ensur
b
cell
express
autoreact
immunoglobulin
purg
cancro
et
al
key
regul
b
cell
matur
function
b
cell
checkpoint
solubl
bli
ligand
b
lymphocyt
stimul
also
known
b
cell
activ
factor
baff
april
proliferationinduc
ligand
bind
receptor
also
known
baffr
promot
b
cell
surviv
bind
transmembran
calcium
modul
cyclophilin
ligandinteractor
taci
b
cell
matur
antigen
bcma
result
ig
class
switch
celldepend
respons
cancro
et
al
overexpress
lead
autoimmun
consequ
system
lupu
erythematosu
sle
syndrom
cancro
et
al
one
b
cell
checkpoint
inhibitor
mab
approv
two
current
phase
iii
clinic
trial
three
phase
iii
clinic
trial
target
b
cell
activ
factor
regulatori
pathway
anoth
approach
gain
interest
recent
year
immunomodul
nk
cell
nk
cell
well
cell
express
seri
inhibitori
receptor
includ
tigit
kir
famili
member
carotta
immun
defens
mechan
tumor
cell
express
ligand
bind
receptor
inhibit
unwant
activ
nk
cell
current
six
antibodi
phase
iii
clinic
trial
bind
target
remov
brake
nk
cell
activ
final
anoth
checkpoint
regul
activ
macrophag
phagocytosi
target
cell
signal
regulatori
protein
alpha
calr
calreticulin
pathway
ligat
often
refer
eat
signal
wherea
ligat
known
eat
signal
mccracken
et
al
block
antibodi
fc
fusion
protein
lead
imbal
pro
eat
respons
mccracken
et
al
current
four
antibodi
fc
fusion
protein
evalu
clinic
trial
treatment
cancer
tabl
one
approach
gain
interest
recent
year
combin
mixtur
antibodi
usual
singl
target
includ
singl
dosag
raju
strohl
carvalho
et
al
thu
far
antibodi
mixtur
use
mostli
oncolog
infecti
diseas
indic
danish
biotechnolog
compani
symphogen
led
space
four
antibodi
mixtur
current
test
clinic
trial
includ
mixtur
two
antiegfr
mab
mixtur
six
antibodi
erbb
receptor
tyrosin
kinas
famili
receptor
ellebaek
et
al
mixtur
two
antibodi
target
met
cmet
undisclos
mixtur
antibodi
partner
genentech
infecti
diseas
target
least
nine
antibodi
mixtur
evalu
clinic
trial
infecti
diseas
target
ebola
viru
botulinum
toxin
virus
one
interest
new
approach
area
could
see
significantli
greater
upsid
come
year
gener
fulli
human
antibodi
mixtur
polyclon
mixtur
transgen
tg
cattl
matsushita
et
al
may
found
safe
efficaci
least
partial
replac
specif
intraven
immunoglobulin
ivig
igg
purifi
individu
vaccin
convalesc
patient
produc
igg
specif
target
llewelyn
et
al
mire
et
al
upsid
tg
cattleproduc
human
igg
suppli
consist
across
lot
abil
vaccin
cow
antigen
avail
human
vaccin
due
regulatori
safeti
consider
one
polyclon
mixtur
tg
cattl
alreadi
evalu
clinic
trial
sab
therapeut
polyclon
mixtur
human
igg
target
middl
east
respiratori
mer
viru
luke
et
al
bispecif
antibodi
first
conceptu
milstein
cuello
antibodi
bind
two
differ
antigen
simultan
five
fundament
group
bispecif
antibodi
format
asymmetr
bival
bispecif
igglik
antibodi
heterodimer
heavi
chain
hc
ridgeway
et
al
merchant
et
al
gunasekaran
et
al
strop
et
al
klein
et
al
labrijn
et
al
von
kreudenstein
et
al
brinkmann
kontermann
ii
tetraval
multispecif
antibodi
compris
igg
addit
bind
domain
eg
scfv
fv
vhh
domain
nonantibodi
bind
scaffold
fynom
brack
et
al
silacci
et
al
fuse
either
n
ctermini
either
heavi
light
chain
lc
coloma
morrison
iii
engin
bind
domain
within
normal
igg
structur
twoinon
bispecif
approach
genentech
bostrom
et
al
eigenbrot
fuh
fstar
approach
design
novel
second
bind
site
within
domain
leung
et
al
iv
engin
antibodi
fragment
link
short
peptid
linker
made
bival
trival
tetraval
format
address
two
three
target
mack
et
al
hollig
winter
kipriyanov
et
al
reusch
et
al
egan
et
al
may
fuse
fc
domain
halflif
extend
molecul
liu
et
al
v
igg
chemic
coupl
gener
iggigg
conjug
eg
brennan
et
al
garrido
et
al
exampl
five
basic
format
shown
fig
mani
variat
central
theme
review
multipl
time
kontermann
spiess
et
al
kontermann
brinkmann
ha
et
al
brinkmann
kontermann
past
decad
liter
explos
novel
bispecif
antibodi
technolog
approach
clinic
candid
today
least
bispecif
bifunct
antibodi
clinic
trial
made
least
differ
bispecif
platform
technolog
tabl
includ
ten
asymmetr
iggbas
platform
bispecif
antibodi
five
append
igg
platform
bispecif
antibodi
singl
platform
chemic
coupl
igg
four
bispecif
antibodi
eight
fragmentbas
platform
bispecif
antibodi
one
iggbas
bispecif
gener
unknown
platform
tabl
two
bispecif
antibodi
thu
far
approv
medic
use
field
oncolog
first
bispecif
antibodi
kind
approv
catumaxomab
bival
trifunct
hybrid
mous
rat
antibodi
target
one
arm
epcam
catumaxomab
approv
european
union
treatment
malign
ascit
gener
threeway
fusion
mous
bcell
rat
bcell
myeloma
cell
form
quadroma
cell
line
technolog
zeidler
et
al
second
bispecif
antibodi
approv
x
bispecif
cell
engag
bite
construct
link
two
scfv
five
residu
linker
mack
et
al
known
blinatumomab
trade
name
approv
treatment
bcell
acut
lymphoblast
leukemia
current
clinic
stage
bispecif
antibodi
use
varieti
differ
purpos
exampl
bind
two
solubl
antigen
eg
nine
bind
two
receptor
cell
surfac
egfr
met
eg
four
bind
cell
surfac
target
delta
like
canon
notch
ligand
one
combin
site
solubl
ligand
vegf
eg
navicixizumab
two
current
clinic
stage
bispecif
antibodi
biparatop
ie
arm
bind
receptor
albeit
two
differ
nonoverlap
epitop
eg
zymework
bind
two
nonoverlap
epitop
signific
use
bispecif
antibodi
howev
cell
redirect
one
combin
site
direct
toward
cell
surfac
target
cancer
cell
combin
site
bind
cell
redirect
cell
target
cancer
cell
see
twentyseven
clinic
stage
bispecif
antibodi
immun
cell
redirect
bispecif
antibodi
one
target
nk
cell
redirect
bispecif
antibodi
target
cell
redirect
cytotox
cell
ctl
kill
lyse
cancer
cell
construct
antibodi
fragment
seven
asymmetr
bispecif
igg
four
conjug
bispecif
igg
use
activ
cell
ex
corpor
brennan
et
al
garrido
et
al
two
bispecif
igg
append
domain
tabl
two
append
igg
also
util
asymmetr
fc
format
one
arm
present
gener
accept
potent
cell
redirect
antibodi
fragment
unmodifi
bite
dart
dualaffin
retarget
antibodi
demonstr
subpicomolar
valu
vitro
kill
activ
moor
et
al
two
approv
antibodi
mous
bite
asymmetr
ratmous
igg
given
first
gener
cell
redirect
fulli
mous
antibodi
differ
indic
difficult
say
today
type
platform
fragment
vs
iggbas
ultim
efficaci
treatment
diseas
larger
iggbas
form
appear
significantli
less
potent
base
vitro
activ
vivo
preclin
dose
fragment
unpublish
data
thu
balanc
sheer
potenc
achiev
small
size
long
halflif
typic
bring
greater
size
less
potenc
addit
size
cell
surfac
receptor
target
cell
epitop
antibodi
bind
appear
critic
factor
potenc
well
bluemel
et
al
moreov
potenc
cell
redirect
bispecif
antibodi
depend
affin
arm
antigen
typic
case
bispecif
cell
redirect
antibodi
affin
cancer
cell
surfac
target
much
higher
ie
affin
chain
cell
zhukovski
et
al
summari
factor
may
influenc
potenc
cell
redirect
antibodi
size
antibodi
size
target
cell
surfac
protein
epitop
protein
antibodi
bind
affin
anoth
area
yet
fulli
investig
respect
cell
redirect
role
fc
function
platform
design
highli
activ
fc
domain
interact
human
increas
immun
respons
cheliu
et
al
hess
et
al
hand
current
fragmentfc
asymmetr
igg
append
igg
platform
use
mute
silenc
fc
stimul
immun
system
via
interact
myeloid
effector
cell
even
absenc
fc
activ
mani
treatment
cell
redirect
bispecif
antibodi
accompani
cytokin
storm
need
address
part
therapeut
paradigm
lee
et
al
thu
seem
like
cell
redirect
antibodi
made
futur
continu
avoid
fc
activ
effort
limit
releas
proinflammatori
cytokin
cell
effector
cell
tumor
microenviron
car
antitumor
target
antibodi
fuse
genet
stalk
linker
transmembran
domain
intracellular
cell
activ
domain
borrow
activ
checkpoint
receptor
andor
fig
figueroa
et
al
van
der
stegen
et
al
ruella
gill
smith
et
al
ruella
june
lim
june
concept
cart
cell
around
sinc
earli
eshhar
et
al
advanc
technolog
requir
turn
viabl
manufactur
process
realiz
recent
year
thu
similar
bispecif
antibodi
technolog
conceptu
old
truli
develop
cart
technolog
still
rel
young
still
develop
lim
june
fundament
two
type
car
first
autolog
patient
cell
collect
process
known
apheresi
either
whole
pool
fraction
pool
cell
cell
possibl
cell
transduc
car
use
either
viral
vector
lentiviru
transposon
sleep
beauti
piggyback
figueroa
et
al
lim
june
recombin
cell
arm
car
target
tumor
express
surfac
activ
infus
back
patient
deriv
kill
cancer
cell
bear
antigen
figueroa
et
al
second
major
type
car
allogen
univers
offtheshelf
cell
line
construct
typic
devoid
mhc
class
molecul
ren
et
al
endogen
cell
receptor
macleod
et
al
ren
et
al
decreas
risk
host
vs
graft
reject
graft
vs
host
diseas
gvhd
respect
univers
cell
line
also
would
express
car
treatment
cancer
possibl
viral
infect
thu
far
barrier
gener
truli
theshelf
allogen
cell
line
still
quit
high
control
prolifer
continu
activ
cell
engraft
incorpor
kill
switch
safeti
purpos
critic
issu
still
work
nevertheless
signific
progress
made
past
year
suggest
fulli
modifi
allogen
cart
cell
therapi
quickli
becom
realiti
ren
et
al
b
date
four
gener
autolog
cart
cell
construct
first
gener
typic
consist
extracellular
cancer
celltarget
scfv
fuse
stalk
transmembran
domain
follow
aka
provid
activ
signal
park
brentjen
figueroa
et
al
lim
june
first
gener
car
possess
ampl
cytotox
lack
prolif
surviv
signal
secondgener
car
typic
link
exodomain
scfv
transmembran
domain
provid
prolifer
signal
follow
provid
cytolyt
activ
signal
third
gener
car
typic
link
target
scfv
transmembran
domain
follow
either
activ
domain
park
brentjen
figueroa
et
al
smith
et
al
lim
june
car
combin
cytolyt
activ
prolifer
surviv
signal
enhanc
activ
persist
patient
serum
fourth
gener
car
add
new
activ
suicid
mechan
kill
car
case
becom
overprolif
util
cell
condit
recogn
viral
antigen
use
vaccin
increas
persist
cart
construct
chmielewski
et
al
smith
et
al
lim
june
current
differ
car
construct
clinic
trial
state
earlier
car
candid
phase
ii
clinic
trial
almost
half
current
car
origin
china
origin
us
origin
europ
car
gener
differ
target
cellsurfac
protein
cancer
cell
one
mhcdisplay
peptid
target
deriv
intracellular
antigen
rafiq
et
al
fiftythre
clinic
car
candid
direct
next
target
antigen
msln
mesothelin
car
car
car
current
clinic
stage
car
construct
autolog
cart
construct
gener
cell
tabl
exampl
format
includ
earli
format
allogen
cart
cell
autolog
car
cell
autolog
allogen
carnk
cell
carnkt
cell
car
made
tcr
tabl
earli
judg
success
car
field
although
clear
area
gener
enorm
amount
interest
well
fund
well
exceed
noteworthi
novarti
recent
file
biolog
licens
applic
bla
us
fda
treatment
relaps
refractori
bcell
acut
lymphoblast
anemia
ball
tisagenlecleucelt
make
first
car
construct
submit
regulatori
approv
kingwel
moreov
kite
pharma
announc
shortli
thereaft
complet
roll
bla
submiss
treatment
nonhodgkin
lymphoma
nhl
use
axicabtagen
ciloleucel
either
approv
within
next
year
mark
huge
mileston
excit
new
field
area
interest
mani
year
proven
challeng
target
antibodi
compart
normal
go
includ
exampl
target
antibodi
gut
via
oral
rout
brain
cross
bloodbrain
barrier
cytosol
intracellular
compart
compart
present
signific
challeng
past
year
signific
stride
made
advanc
tissuetarget
antibodybas
product
bonetarget
enzym
replacementfc
fusion
asfotas
alpha
approv
us
fda
treatment
hypophosphatasia
hofman
et
al
asfotas
alpha
tnsalpfcdecaaspart
fusion
protein
target
bone
decaaspart
peptid
fuse
cterminu
fc
millan
et
al
second
area
antibodi
target
repres
clinic
candid
base
rout
deliveri
get
antibodi
desir
compart
least
three
orallydeliv
antibodyrel
protein
target
intestin
tract
current
evalu
clinic
trial
includ
antitnf
plant
cellexpress
deliv
fc
fusion
protein
phase
ii
clinic
trial
treatment
ulcer
coliti
ilan
et
al
plant
cell
thought
protect
fc
fusion
travers
stomach
last
decad
mous
mab
evalu
clinic
trial
oral
deliveri
gut
treatment
nonalcohol
steatohepat
nash
result
suggest
clinic
activ
lalazar
et
al
second
mab
formul
oral
deliveri
foralumab
novimmun
tiziana
life
scienc
fulli
human
mab
current
prepar
phase
ii
clinic
trial
oral
deliveri
treatment
nash
get
antibodi
cross
bloodbrain
barrier
goal
well
two
decad
igg
level
human
brain
approxim
serum
concentr
mgml
abbott
et
al
differenti
due
bloodbrain
barrier
bbb
effect
keep
antibodi
brain
consid
wealth
potenti
target
biolog
central
nervou
system
cn
great
effort
find
mechan
improv
abil
transloc
biolog
cn
recent
year
signific
progress
made
get
antibodi
travers
bbb
yu
et
al
use
bival
bispecif
antibodi
bind
tfrc
transferrin
receptor
one
arm
arm
demonstr
low
affin
antibodi
tfrc
effici
transcytosi
high
affin
antibodi
achiev
higher
accumul
antibodi
brain
control
clearli
demonstr
pharmacolog
activ
antibodi
prove
antibodi
accumul
within
brain
yu
et
al
also
gener
bival
bispecif
antibodi
target
human
nonhuman
primat
nhp
tfrc
one
arm
human
arm
yu
et
al
best
variant
lowtomoder
affin
antibodi
tfrc
accumul
higher
brain
control
antibodi
demonstr
vivo
pharmacolog
activ
nhp
yu
et
al
neiwoehn
et
al
compar
effici
transcytosi
use
tetraval
bispecif
antibodi
two
arm
bind
tfrc
app
amyloidbeta
trival
bispecif
antibodi
one
arm
bind
tfrc
found
monoval
bind
tfrc
promot
effici
transcytosi
wherea
bival
bind
tfrc
result
shuttl
complex
toward
lysosom
degrad
demonstr
improv
target
engag
control
neiwoehn
et
al
contrast
studi
monoval
target
transcytot
receptor
optim
sialoglycoprotein
llama
singledomain
antibodi
abulrob
et
al
appear
transcytos
effici
dimer
rather
monom
farrington
et
al
recent
fuse
scfv
format
nterminu
hc
antigrm
glutam
metabotrop
receptor
antagonist
igg
shuttl
across
bbb
webster
et
al
achiev
pharmacolog
activ
enrich
antibodi
brain
parenchyma
webster
et
al
thu
still
appear
much
learn
optim
antibodi
transcytot
deliveri
protein
cn
william
pardridg
colleagu
isol
antihuman
insr
insulin
receptor
antibodi
transcytos
insr
endotheli
cell
line
vasculatur
brain
boado
et
al
use
antiinsr
antibodi
transcytot
carrier
move
enzym
across
bbb
cn
enzym
replac
therapi
ert
boado
et
al
candid
construct
fusion
enzym
cterminu
bbbtravers
antiinsr
igg
hirmab
boado
et
al
tetraval
two
antibodi
arm
two
enzym
fusion
antiinsr
antibodi
ali
boado
et
al
evalu
phase
clinic
trial
treatment
mucopolysaccharidosi
mp
hurler
syndrom
recent
demonstr
taken
nonhuman
primat
brain
inject
dose
compar
inject
dose
alon
boado
pardridg
demonstr
pharmacolog
relev
bbbtravers
bispecif
antibodi
compris
fusion
iduron
id
ctermini
antiinsr
hc
boado
et
al
phase
clinic
test
treatment
mucopolysaccharidosi
ii
mp
ii
hunter
syndrom
final
deliveryrel
technolog
gotten
interest
recent
year
deliveri
mab
cytosol
cell
via
pinocytosi
endosom
escap
marschal
et
al
et
al
stewart
et
al
lim
et
al
multipl
approach
taken
get
biolog
activ
antibodi
cytosol
cell
includ
use
cell
penetr
peptid
marschal
et
al
et
al
lim
et
al
recent
uniqu
antibodi
gener
deliveri
igg
cytosol
cell
via
endosom
escap
choi
et
al
antibodi
uniqu
sequenc
light
chain
variabl
region
matur
increas
proport
igg
enter
cytoplasm
kim
et
al
cell
penetr
technolog
marschal
et
al
et
al
lim
et
al
bring
hope
one
day
antibodi
use
target
cytosol
antigen
tradit
form
deliveri
mab
fc
fusion
protein
via
either
intraven
iv
subcutan
sc
administr
formul
protein
gener
high
dose
mab
oncolog
indic
limit
iv
dose
wherea
low
dose
antibodi
adalimumab
golimumab
ustekinumab
easili
deliv
sc
dose
addit
recent
year
increas
interest
intratumor
dose
antibodi
biolog
certain
type
cancer
tumor
access
zeltsman
et
al
novel
approach
deliv
mab
andor
fc
fusion
protein
via
deliveri
gene
gene
produc
either
nake
dna
rna
viralbas
vector
entir
new
approach
sinc
studi
done
around
turn
centuri
show
rna
giraud
et
al
viral
lewi
et
al
deliveri
igg
gene
could
result
demonstr
vivo
igg
activ
nevertheless
much
interest
past
year
becom
evid
vector
nucleic
acid
deliveri
igg
could
potenti
signific
new
approach
deliv
antibodi
therapeut
use
one
excit
form
deliveri
intramuscular
inject
adenoassoci
virus
aav
encod
antibodi
follow
year
consist
high
express
antibodi
nonhuman
primat
fuch
et
al
greig
et
al
import
note
aav
exist
muscl
cell
extrachromosom
element
integr
increas
safeti
use
long
term
express
antibodi
protein
greig
et
al
suggest
approach
might
appropri
deliveri
antihiv
antibodi
help
patient
either
becom
cure
minim
less
reliant
highli
activ
antiretrovir
therapi
haart
schnepp
johnson
fuch
desrosi
sever
promis
potent
antihiv
antibodi
clinic
trial
current
express
vivo
use
genebas
deliveri
antibodi
potenti
therapeut
use
schnepp
johnson
yang
wang
fuch
et
al
fuch
desrosi
similarli
differ
twist
aavdeliv
antibodi
nasal
passag
mice
demonstr
excel
prophylaxi
flu
viru
limberi
et
al
balaz
et
al
adam
et
al
sinc
aav
enter
epitheli
cell
slough
sever
month
provid
potenti
safe
rout
deliveri
prophylact
antiflu
antibodi
would
cover
entir
flu
season
potenti
signific
approach
sever
habind
neutral
antibodi
avail
nearli
univers
influenza
viru
inhibitor
could
potenti
use
clinic
trial
determin
whether
prophylact
paninfluenza
nasal
deliveri
approach
might
feasibl
final
concept
use
oncolyt
virus
deliv
antitumor
checkpoint
modul
antibodi
tumor
excit
oncolyt
virus
engin
year
deliv
immunemodul
molecul
gmcsf
tme
bommareddi
et
al
make
sens
could
engin
deliv
tme
modul
antibodi
du
et
al
sever
recent
exampl
demonstr
potenti
variou
type
oncolyt
virus
express
immun
checkpoint
inhibitor
du
et
al
kleinpet
et
al
tanou
et
al
well
antitumor
antibodi
adelfing
et
al
liikanen
et
al
fajardo
et
al
past
decad
signific
shift
discoveri
develop
basic
antibodi
eg
nake
isotyp
antibodi
addit
engin
perhap
human
affin
matur
sophist
form
antibodi
kind
shape
size
newer
form
includ
fcmodifi
glycoengin
bispecif
drugconjug
cell
surfac
express
antibodi
ie
car
new
weapon
fight
difficult
treat
diseas
see
dramat
shift
type
number
modifi
antibodi
reach
clinic
trial
studi
new
phase
antibodi
drug
discoveri
develop
repres
excit
bold
new
era
see
antibodybas
therapeut
expand
influenc
mani
type
diseas
next
year
like
see
first
regulatori
approv
cart
base
antibodi
immunocytokin
well
approv
addit
new
bispecif
antibodi
new
adc
fc
engin
antibodi
glycoengin
antibodi
addit
see
new
advanc
target
antibodi
cn
intracellular
compart
well
nucleic
acid
viralvector
deliveri
excit
time
antibodi
engin
